Retatrutide Peptide - GLP-1/GIP/Glucagon Triple Agonist

Retatrutide for Research: Complete Scientific Overview

Retatrutide (LY3437943) is a groundbreaking unimolecular triple agonist developed for metabolic research. Unlike selective GLP-1 agonists or dual GIP/GLP-1 agonists, Retatrutide uniquely activates three distinct incretin receptors: GLP-1, GIP, and glucagon (GCG). This triple agonism provides complementary and potentially synergistic metabolic effects, making it one of the most advanced research peptides in the incretin class. The peptide is engineered with a C20 fatty diacid moiety that enables strong albumin binding, resulting in an extended half-life suitable for once-weekly dosing in research protocols.

Mechanism of Action

Retatrutide acts as a balanced agonist at three distinct receptors:

• GLP-1 Receptor: Enhances glucose-dependent insulin secretion from pancreatic β-cells, suppresses glucagon release from α-cells, delays gastric emptying, and activates central satiety pathways in the hypothalamus, promoting reduced food intake.
• GIP Receptor: Improves first-phase insulin secretion, enhances lipid buffering capacity in adipose tissue, contributes to metabolic homeostasis, and exerts direct beneficial effects on adipocyte function and lipid metabolism.
• Glucagon (GCG) Receptor: Increases energy expenditure, promotes lipolysis and fatty acid oxidation, enhances thermogenesis, and stimulates hepatic glucose production in a controlled manner that complements the actions of GLP-1 and GIP.

The triple agonist design uniquely combines the anabolic benefits of GLP-1/GIP activation with the catabolic effects of glucagon receptor activation, offering a comprehensive approach to metabolic research. This balanced triple activation represents a significant advancement over single or dual agonists, as it simultaneously addresses multiple aspects of metabolic dysregulation.

Structural Characteristics

Retatrutide is a 39-amino acid peptide incorporating non-canonical amino acids including α-aminoisobutyric acid (Aib) at positions 2 and 13, which confer resistance to DPP-4 degradation, enhancing plasma stability. The peptide features a C-terminal amide group that improves stability and a C20 fatty diacid conjugated to lysine at position 20 via a glutamic acid linker, enabling reversible albumin binding for extended half-life. These structural innovations make Retatrutide an excellent tool for long-term metabolic research studies requiring sustained receptor activation.

Research Applications

• Triple Incretin Receptor Pharmacology: Characterizing the distinct and combined signaling pathways activated by simultaneous GLP-1, GIP, and glucagon receptor engagement
• Energy Expenditure Research: Investigating the effects of triple agonism on basal metabolic rate, thermogenesis, and overall energy balance
• Lipid Metabolism Studies: Examining the role of triple incretin activation in fatty acid oxidation, lipolysis, and lipid partitioning
• Glucose Homeostasis: Understanding the integrated effects of triple agonism on insulin secretion, insulin sensitivity, and glucagon regulation
• Appetite Regulation: Studying central GLP-1, GIP, and glucagon receptor pathways in feeding behavior, satiety, and reward processing
• Comparative Receptor Pharmacology: Comparing signaling bias, receptor internalization, and desensitization across GLP-1R, GIPR, and GCGR
• Metabolic Syndrome Models: Evaluating the therapeutic potential of triple agonism in preclinical models of metabolic dysfunction
• Cardiometabolic Research: Investigating the cardiovascular effects of balanced GLP-1, GIP, and glucagon receptor activation

Chemical Information

CAS Number: 2381089-83-2
Research Code: LY3437943
Molecular Formula: C221H342N46O68
Molecular Weight: 4735.4 g/mol
Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Purity: >99% (HPLC)
Form: Lyophilized powder
Storage: -20°C (lyophilized), 4°C (reconstituted)
Stability: Stable at -20°C for 24 months; reconstituted solution stable at 4°C for 30 days

Reconstitution and Handling Protocols

For optimal stability and research validity, Retatrutide should be reconstituted with sterile bacteriostatic water or sterile saline (0.9% NaCl). Allow the lyophilized powder to dissolve completely without vigorous shaking to maintain peptide integrity. Gently swirl the vial until the solution is clear and free of particulates. Once reconstituted, the solution should be stored at 4°C and used within 30 days. Avoid repeated freeze-thaw cycles to preserve peptide structure and biological activity. For long-term storage, keep the lyophilized powder at -20°C away from light and moisture. Do not vortex or vigorously shake the reconstituted solution, as this may cause aggregation and reduce biological activity.